These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 18308513)
1. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Leucht S; Shamsi SA; Busch R; Kissling W; Kane JM Schizophr Res; 2008 Apr; 101(1-3):312-9. PubMed ID: 18308513 [TBL] [Abstract][Full Text] [Related]
2. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317 [TBL] [Abstract][Full Text] [Related]
3. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon BJ; Roychowdhury SM; Milton DR; Hill AL J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746 [TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez JC; Crawford AM J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753 [TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331 [TBL] [Abstract][Full Text] [Related]
6. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Leucht S; Busch R; Kissling W; Kane JM J Clin Psychiatry; 2007 Mar; 68(3):352-60. PubMed ID: 17388703 [TBL] [Abstract][Full Text] [Related]
7. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553 [TBL] [Abstract][Full Text] [Related]
8. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Stauffer VL; Case M; Kinon BJ; Conley R; Ascher-Svanum H; Kollack-Walker S; Kane J; McEvoy J; Lieberman J Psychiatry Res; 2011 May; 187(1-2):42-8. PubMed ID: 21168920 [TBL] [Abstract][Full Text] [Related]
9. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Stentebjerg-Olesen M; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Jeppesen P; Correll CU Eur Child Adolesc Psychiatry; 2015 Dec; 24(12):1485-96. PubMed ID: 26032132 [TBL] [Abstract][Full Text] [Related]
10. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985 [TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus haloperidol treatment in first-episode psychosis. Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301 [TBL] [Abstract][Full Text] [Related]
12. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson GD; Sanger TM Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332 [TBL] [Abstract][Full Text] [Related]
13. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577 [TBL] [Abstract][Full Text] [Related]
14. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotic drug effects on brain morphology in first-episode psychosis. Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M; Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403 [TBL] [Abstract][Full Text] [Related]
17. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France]. Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ Encephale; 1999; 25(4):281-6. PubMed ID: 10546082 [TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534 [TBL] [Abstract][Full Text] [Related]
19. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited. Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198 [TBL] [Abstract][Full Text] [Related]